| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
-Difluoromethylornithine, an Ornithine Decarboxylase Inhibitor, in Diet1
Division of Nutrition and Endocrinology [B. S. R., J. N.], Division of Pathology and Toxicology [K. T.], Research Animal Facility [J. R.], and Division of Epidemiology and Biostatistics [E. Z.], Naylor Dana Institute for Disease Prevention, American Health Foundation, Valhalla, New York 10595, and Chemoprevention Branch, Division of Cancer Control and Prevention, National Cancer Institute, Bethesda, Maryland 20892 [G. K.]
The effect of three levels of piroxicam and three levels of D,L-
-difluoromethylornithine (DFMO) fed individually and in combination during the postinitiation phase of carcinogenesis was studied in male F344 rats to generate a data base on the efficacy and synergistic and additive effects of these compounds as inhibitors of colon carcinogenesis. The maximum tolerated dose of DFMO was determined in male F344 rats and found to be 5000 ppm in the AIN-76A diet. Piroxicam at levels of 25, 75, and 150 ppm and DFMO at concentrations of 400, 1000, and 4000 ppm (20, 50, and 80% maximum tolerated dose) in AIN-76 diet were tested individually and in combinations. At 7 weeks of age, while the rats were consuming the control diet (AIN-76A), all animals except the vehicle (saline) — treated controls were given a single s.c. injection of azoxymethane (CAS: 25843-45-2) at a dose level of 29.6 mg/kg body weight to induce intestinal tumors. One week after azoxymethane injection, animals were transferred to their respective experimental diets containing piroxicam and DFMO. Fifty-six weeks after azoxymethane injection, all animals were necropsied and colon and small intestinal tumor incidences and multiplicity were compared among the various dietary groups. Feeding of diets containing 75 and 150 ppm piroxicam or 1000 and 4000 ppm DFMO significantly inhibited the incidence (percentage of animals with tumors) of colon adenocarcinomas compared to that of control diet. The multiplicity (number of tumors/rat) of adenocarcinomas was significantly inhibited in animals fed the 25, 75, and 150 ppm piroxicam or 400, 1000, and 4000 ppm DFMO diets. Results analyzed by the linear regression method suggested a dose-dependent inhibition in colon adenocarcinoma incidence with increasing levels of piroxicam or DFMO. The incidence and multiplicity of colon adenocarcinomas were significantly inhibited in animals fed the diets containing combinations of 25, 75, and 150 ppm piroxicam and 400, 1000, and 4000 ppm DFMO. Piroxicam and DFMO administered together had a stronger inhibitory effect than did those given individually. Piroxicam and DFMO when administered individually had no significant inhibitory effect on colon adenoma incidence and multiplicity; in contrast, combinations of these compounds significantly inhibited colon adenomas. No consistent differences were found in the incidence and multiplicity of small intestinal tumors among the dietary groups. The results of this study indicate that (a) increasing levels of piroxicam and DFMO in the diet inhibited colon adenocarcinomas in a dose-dependent manner, and (b) the administration of piroxicam and DFMO together was more effective than those administered individually in suppressing the colon adenoma and adenocarcinoma development.
1 This investigation was supported by USPHS Contract NO1CN-45191-04 from the National Cancer Institute. Animals were maintained under the guidelines set forth in the "Guide for the Care and Use of Laboratory Animal Resources" by the National Research Council.
2 To whom requests for reprints should be addressed.
Received 10/ 4/89.
Revised 1/22/90.
This article has been cited by other articles:
|
|
 |
|
  B. S. Reddy, C. X. Wang, A.-N. Kong, T. O. Khor, X. Zheng, V. E. Steele, L. Kopelovich, and C. V. Rao Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in f 344 rats. Cancer Res., April 15, 2006; 66(8): 4542 - 4546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-H. Kim, C. Xu, Y.-S. Keum, B. Reddy, A. Conney, and A.-N. T. Kong Inhibition of EGFR signaling in human prostate cancer PC-3 cells by combination treatment with {beta}-phenylethyl isothiocyanate and curcumin Carcinogenesis, March 1, 2006; 27(3): 475 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. O. Khor, Y.-S. Keum, W. Lin, J.-H. Kim, R. Hu, G. Shen, C. Xu, A. Gopalakrishnan, B. Reddy, X. Zheng, et al. Combined Inhibitory Effects of Curcumin and Phenethyl Isothiocyanate on the Growth of Human PC-3 Prostate Xenografts in Immunodeficient Mice Cancer Res., January 15, 2006; 66(2): 613 - 621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. Narayanan, N. K. Narayanan, D. Desai, B. Pittman, and B. S. Reddy Effects of a combination of docosahexaenoic acid and 1,4-phenylene bis(methylene) selenocyanate on cyclooxygenase 2, inducible nitric oxide synthase and {beta}-catenin pathways in colon cancer cells Carcinogenesis, December 1, 2004; 25(12): 2443 - 2449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Pereira, L. Tao, W. Wang, Y. Li, A. Umar, V. E. Steele, and R. A. Lubet Modulation by celecoxib and difluoromethylornithine of the methylation of DNA and the estrogen receptor-{alpha} gene in rat colon tumors Carcinogenesis, October 1, 2004; 25(10): 1917 - 1923. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Guo, R. M. Ray, and L. R. Johnson RhoA stimulates IEC-6 cell proliferation by increasing polyamine-dependent Cdk2 activity Am J Physiol Gastrointest Liver Physiol, October 1, 2003; 285(4): G704 - G713. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. E. Hardman Omega-3 Fatty Acids to Augment Cancer Therapy J. Nutr., November 1, 2002; 132(11): 3508S - 3512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Carlton, R. Gopalakrishnan, A. Gupta, B. W. Liston, S. Habib, M. A. Morse, and G. D. Stoner Piroxicam Is an Ineffective Inhibitor of N-Nitrosomethylbenzylamine-induced Tumorigenesis in the Rat Esophagus Cancer Res., August 1, 2002; 62(15): 4376 - 4382. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Zhang, J. Li, L. E. Lantry, Y. Wang, R. W. Wiseman, R. A. Lubet, and M. You p53 Transgenic Mice Are Highly Susceptible to 1, 2-Dimethylhydrazine-induced Uterine Sarcomas Cancer Res., June 1, 2002; 62(11): 3024 - 3029. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Thun, S. J. Henley, and C. Patrono Nonsteroidal Anti-inflammatory Drugs as Anticancer Agents: Mechanistic, Pharmacologic, and Clinical Issues J Natl Cancer Inst, February 20, 2002; 94(4): 252 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. V. Rao, C. Indranie, B. Simi, P. T. Manning, J. R. Connor, and B. S. Reddy Chemopreventive Properties of a Selective Inducible Nitric Oxide Synthase Inhibitor in Colon Carcinogenesis, Administered Alone or in Combination with Celecoxib, a Selective Cyclooxygenase-2 Inhibitor Cancer Res., January 1, 2002; 62(1): 165 - 170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Green, M.-A. Shibata, E. Shibata, R. C. Moon, M. R. Anver, G. Kelloff, and R. Lubet 2-Difluoromethylornithine and Dehydroepiandrosterone Inhibit Mammary Tumor Progression but not Mammary or Prostate Tumor Initiation in C3(1)/SV40 T/t-antigen Transgenic Mice Cancer Res., October 1, 2001; 61(20): 7449 - 7455. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. N. DuBois New paradigms for cancer prevention Carcinogenesis, May 1, 2001; 22(5): 691 - 692. [Full Text] [PDF]
|
|
|
|
|
|
S. M. Fischer, M. Lee, and R. A. Lubet Difluoromethylornithine is effective as both a preventive and therapeutic agent against the development of UV carcinogenesis in SKH hairless mice Carcinogenesis, January 1, 2001; 22(1): 83 - 88. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Calaluce, D. L. Earnest, D. Heddens, J. G. Einspahr, D. Roe, C. L. Bogert, J. R. Marshall, and D. S. Alberts Effects of Piroxicam on Prostaglandin E2 Levels in Rectal Mucosa of Adenomatous Polyp Patients: A Randomized Phase IIb Trial Cancer Epidemiol. Biomarkers Prev., December 1, 2000; 9(12): 1287 - 1292. [Abstract] [Full Text]
|
|
|
|
|
|
K. R. Lawson, N. A. Ignatenko, G. A. Piazza, H. Cui, and E. W. Gerner Influence of K-ras Activation on the Survival Responses of Caco-2 Cells to the Chemopreventive Agents Sulindac and Difluoromethylornithine Cancer Epidemiol. Biomarkers Prev., November 1, 2000; 9(11): 1155 - 1162. [Abstract] [Full Text]
|
|
|
|
|
|
Y. Guo, R. B. Harris, D. Rosson, D. Boorman, and T. G. O’Brien Functional Analysis of Human Ornithine Decarboxylase Alleles Cancer Res., November 1, 2000; 60(22): 6314 - 6317. [Abstract] [Full Text]
|
|
|
|
|
|
R. F. Jacoby, C. E. Cole, K. Tutsch, M. A. Newton, G. Kelloff, E. T. Hawk, and R. A. Lubet Chemopreventive Efficacy of Combined Piroxicam and Difluoromethylornithine Treatment of Apc Mutant Min Mouse Adenomas, and Selective Toxicity against Apc Mutant Embryos Cancer Res., April 1, 2000; 60(7): 1864 - 1870. [Abstract] [Full Text]
|
|
|
|
|
|
B. S. Reddy Novel Approaches to the Prevention of Colon Cancer by Nutritional Manipulation and Chemoprevention Cancer Epidemiol. Biomarkers Prev., March 1, 2000; 9(3): 239 - 247. [Abstract] [Full Text]
|
|
|
|
|
|
P. F. Coogan, L. Rosenberg, J. R. Palmer, B. L. Strom, A. G. Zauber, P. D. Stolley, and S. Shapiro Nonsteroidal Anti-Inflammatory Drugs and Risk of Digestive Cancers at Sites Other Than the Large Bowel Cancer Epidemiol. Biomarkers Prev., January 1, 2000; 9(1): 119 - 123. [Abstract] [Full Text]
|
|
|
|
|
|
Prevention of Cancer in the Next Millennium: Report of the Chemoprevention Working Group to the American Association for Cancer Research Cancer Res., October 1, 1999; 59(19): 4743 - 4758. [Full Text] [PDF]
|
|
|
|
|
|
J. M. Arbeit, R. R. Riley, B. Huey, C. Porter, G. Kelloff, R. Lubet, J. M. Ward, and D. Pinkel Difluoromethylornithine Chemoprevention of Epidermal Carcinogenesis in K14-HPV16 Transgenic Mice Cancer Res., August 1, 1999; 59(15): 3610 - 3620. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Li, H. A.J. Schut, P. Conran, P. M. Kramer, R. A. Lubet, V. E. Steele, E. E. Hawk, G. J. Kelloff, and M. A. Pereira Prevention by aspirin and its combination with {alpha}-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon Carcinogenesis, March 1, 1999; 20(3): 425 - 430. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Shao, H. Sheng, R. Aramandla, M. A. Pereira, R. A. Lubet, E. Hawk, L. Grogan, I. R. Kirsch, M. K. Washington, R. D. Beauchamp, et al. Coordinate regulation of cyclooxygenase-2 and TGF-ß1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors Carcinogenesis, February 1, 1999; 20(2): 185 - 191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. C. Kim, Y. Zhu, V. Andersen, D. Sciaky, H. J. Cao, H. Meekins, T. J. Smith, and P. Lance Cytokine-mediated PGE2 expression in human colonic fibroblasts Am J Physiol Cell Physiol, October 1, 1998; 275(4): C988 - C994. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Martinez, T. Sanchez, and J. J. Moreno Role of prostaglandin H synthase-2-mediated conversion of arachidonic acid in controlling 3T6 fibroblast growth Am J Physiol Cell Physiol, November 1, 1997; 273(5): C1466 - C1471. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
